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Neuroinflammation is thought to contribute to Alzheimer’s disease (AD) pathogenesis
that is, to a large extent, mediated by microglia. Given the tight interaction between
the immune system and the brain, peripheral immune challenges can profoundly affect
brain function. Indeed, both preclinical and clinical studies have indicated that an
aberrant inflammatory response can elicit behavioral impairments and cognitive deficits,
especially when the brain is in a vulnerable state, e.g., during early development,
as a result of aging, or under disease conditions like AD. However, how exactly
peripheral immune challenges affect brain function and whether this is mediated by
aberrant microglial functioning remains largely elusive. In this review, we hypothesize that:
(1) systemic immune challenges occurring during vulnerable periods of life can increase
the propensity to induce later cognitive dysfunction and accelerate AD pathology;
and (2) that “priming” of microglial cells is instrumental in mediating this vulnerability.
We highlight how microglia can be primed by both neonatal infections as well as by
aging, two periods of life during which microglial activity is known to be specifically
upregulated. Lasting changes in (the ratios of) specific microglial phenotypes can result
in an exaggerated pro-inflammatory cytokine response to subsequent inflammatory
challenges. While the resulting changes in brain function are initially transient, a
continued and/or excess release of such pro-inflammatory cytokines can activate various
downstream cellular cascades known to be relevant for AD. Finally, we discuss microglial
priming and the aberrant microglial response as potential target for treatment strategies
for AD.
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INTRODUCTION
Alzheimer’s disease (AD) is characterized by a marked and progressive deterioration of many brain
regions, among others those involved in cognitive function and memory. Neuronal loss, synaptic
degeneration, accumulation of extracellular amyloid-beta deposits and intracellular neurofibrillary
tangles, and an increase in neuro-inflammatory markers are commonly seen in the AD brain
(Querfurth and LaFerla, 2010; Rubio-Perez and Morillas-Ruiz, 2012).
Aside from astrogliosis and increased cytokine levels, it is widely accepted that microglia-
mediated neuroinflammation contributes strongly to the etiology of neurodegeneration
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and AD (Yoshiyama et al., 2007; Hickman et al., 2008; Streit
et al., 2009; Cunningham, 2013; Mhatre et al., 2015). Indeed,
excessive microglial activation and a chronic pro-inflammatory
neurotoxic environment contribute to neurodegeneration and
cognitive dysfunction (Qin et al., 2007; Bodea et al., 2014; Lim
et al., 2015; Wang et al., 2016), similar to what is seen in AD. The
hypothesis that neuroinflammation contributes to AD is further
supported by studies showing that chronic use of nonsteroidal
anti-inflammatory drugs (NSAIDs) appears to delay the onset of
AD (Etminan et al., 2003; Vlad et al., 2008).
Although the brain was long considered an ‘‘immunologically
privileged’’ site, there is a tight communication between both the
peripheral and the central innate immune system, that permits
peripheral immune challenges to influence brain function.
Common routes of communication between these systems
include e.g., a direct access of peripheral cytokines into the brain
at sites where the blood-brain barrier (BBB) is leaky. Transport
of peripheral signals across the BBB occurs by tightly controlled
carrier systems, or via neural afferent pathways such as the
vagal nerve. Also, in response to peripheral stimuli, inflammatory
factors can be secreted by the BBB itself (Bluthé et al., 1994, 2000;
Quan and Banks, 2007; Banks, 2015).
Indeed, evidence for this communication between the
peripheral and central innate immune system comes from the
classic induction of ‘‘non-specific symptoms of sickness’’ during
the course of a systemic infection that makes an individual
change his/her appetite, feel like sleeping and retract from his/her
daily activities and social interactions (Dantzer and Kelley, 2007).
Given the transient nature of most systemic infections, they
are generally considered to have limited lasting consequences
for brain function in general, or for microglial activation in
particular.
Evidence in the last decade, however, indicates that even mild
systemic infections can already have deleterious consequences
for the brain, particularly when they occur during vulnerable
periods, for example during brain development (Adams-
Chapman and Stoll, 2006; Bilbo and Schwarz, 2009) or in the aged
brain (Dilger and Johnson, 2008; Sparkman and Johnson, 2008).
So far, it remains unclear how a normal homeostatic
response to peripheral immune stimuli, may derail into an
altered deleterious inflammatory response involving microglia
in the brain. Since the occurrence of systemic infections
cannot be prevented, it is however crucial to understand
the mechanism(s) by which systemic insults contribute to an
increased susceptibility to later cognitive and neurodegenerative
diseases.
In this review, we will focus on the growing body of evidence
from both preclinical and clinical studies suggesting that acute
systemic infections may serve as an etiological and predisposing
factor for AD. We hypothesize: (1) that systemic immune
challenges occurring during periods when the brain is in a
vulnerable state, may increase the propensity to induce cognitive
decline and AD pathology; and (2) that long-term alterations
in microglial function and responsivity, defined as microglial
‘‘priming’’, may underlie this vulnerability.
We propose that, following infection neonatally or during
aging, microglial cells can become persistently more susceptible
and responsive to peripheral immune challenges whereas this
does not seem to occur during the period of adulthood
when microglia appear less sensitive. Furthermore, while first
peripheral infections trigger microglia to release cytokines, a
secondary insult could induce now ‘‘primed’’ microglia to
release an excess of pro-inflammatory cytokines. This microglial
response can have detrimental downstream consequences for
neuronal functioning that eventually may contribute to cognitive
and behavioral deficits and/or accelerate AD pathology.
MICROGLIA: IMMUNE CELLS OF THE CNS
Sensitivity of Microglial Cells Throughout
Life
Microglial cells in the mature brain continuously, and actively,
survey their environment in order to detect potentially harmful
or pathological stimuli (Nimmerjahn et al., 2005). Microglia
are highly dynamic cells regulating the CNS response to
antigens and inflammation (Norden and Godbout, 2013), by
rapidly responding to pathogens with expression of specific
cytokines, e.g., interleukin 1 and 6 (Van Dam et al., 1992,
1995). Besides continued immune surveillance and mediating
inflammatory responses within the brain, microglia contribute
to neuronal function (Nimmerjahn et al., 2005; Ransohoff
and Perry, 2009; Green and Nolan, 2014; O’Connor et al.,
2014; Heppner et al., 2015; Hong et al., 2016) and to brain
development, and also to neuronal plasticity throughout life
(Sierra et al., 2010; Das and Basu, 2011; Paolicelli et al.,
2011).
In contrast to healthy adult brains, the developing brain
contains activated microglial cells accompanied by cytokine
and chemokine expression (Pousset, 1994; Streit, 2001; Bilbo
and Schwarz, 2009; Schwarz et al., 2012). For instance,
the microglial derived pro-inflammatory cytokines IL-1β and
TNFα are expressed at high levels in the developing CNS
(Gilmore et al., 2004; Schmitz and Chew, 2008). Also a
TNFα knockout model indicates an active involvement in
brain development (Golan et al., 2004). Changes in microglial
activation or cytokine expression levels throughout this period
can furthermore disturb neuronal development, and affect
e.g., cell migration, proliferation, differentiation or synaptic
maturation (Giulian et al., 1988; Mehler and Kessler, 1997; Ben-
Hur et al., 2003; Gilmore et al., 2004; Deverman and Patterson,
2009).
On the other end of the spectrum, also aging is associated
with an aberrant (neuro) immunological response that has
been suggested to result from an overall deterioration of the
immune system (Sierra et al., 2007; Frank et al., 2010), a
process referred to as immune senescence (Ron-Harel and
Schwartz, 2009). The alterations in immune cells cause a
decreased ability to fight infections and result in a heightened
susceptibility of elderly individuals to infectious diseases (Castle,
2000; Zanni et al., 2003). Immunosenescence also occurs
in the brain and is thought to involve aging of microglia.
Microglial aging is generally reflected by an increased pro-
inflammatory state that may result from a switch from a resting
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microglial phenotype in the adult condition, towards a more
reactive and activated phenotype that emerges with increasing
age (Luo et al., 2010; Harry, 2013). Given their important,
powerful and well-regulated roles in the brain, changes in
the levels of pro-inflammatory cytokines during development
or aging may impact brain function, as will be addressed
below.
The Acute and Lasting Effects of Perinatal
Infection on Microglial Cells
To assess the effects of systemic infections on CNS function
in animal models, infections are mostly induced by bacteria
as Escherichia coli (E. coli) or the gram-negative bacterial
component lipopolysaccharide (LPS). Both prenatal and
postnatal infections enhance microglial activity and result in
increased levels of pro-inflammatory cytokines IL-1β, IL-6
and TNFα in the developing brain within hours after LPS
administration (Cai et al., 2000; Paintlia et al., 2004; Billiards
et al., 2006; Liverman et al., 2006; Dinel et al., 2014) or E. coli
infection (Bilbo et al., 2005a). Next to perinatal infection,
inflammatory insults in the brain during the perinatal period
can also occur in response to injuries in the developing brain,
such as ischemia or stroke, or as a (cause and) consequence
of preterm birth (for reviews see Hagberg et al., 2012, 2015).
For instance, hypoxia-ischemia in neonatal rodents induces
a pro-inflammatory state including microglial activation,
increased pro-inflammatory cytokine expression and chemokine
expression in the first hours to day(s) after the insult (Hagberg
et al., 1996; Ivacko et al., 1997; Hedtjärn et al., 2004). These
findings are further supported by clinical studies; preterm
children e.g., have elevated levels of inflammation-related
factors (Duggan et al., 2001; O’Shea et al., 2013), while 6
years later, their immune response is still altered (Lin et al.,
2010). It has furthermore been hypothesized that inflammation
occurring during this vulnerable period of brain development
(Schoderboeck et al., 2009) may lastingly alter, or program,
microglial function for the remainder of life (Bilbo and Schwarz,
2009; Krstic et al., 2012).
Indeed, several studies have demonstrated such a ‘‘priming-
like’’ effect of a primary exposure to early-life infection on
microglial cells, resulting in a more exaggerated microglial
response following re-exposure to a similar immune stimulation.
The microglial cell activity marker complement receptor 3
(CD11b) was for instance elevated in adult rats that were infected
as neonates at P4 (Bilbo et al., 2005a). Also, expression of major
histocompatibility complex II (MHCII), a marker of reactive
microglia, or the pro-inflammatory cytokine response per se, was
markedly elevated after a peripheral LPS challenge in adult rats
that had been infected during early-life (Bilbo et al., 2005a; Bilbo
and Schwarz, 2009).
Given the apparent sensitivity of microglia during the period
of early-life, the timing of an immunological challenge is very
important when considering possible lasting effects. During
development, microglia colonize the (rat) brain from E11
onwards and have acquired a fully adult, ramified morphology
around postnatal day 15 (P15; Schwarz et al., 2012; Harry,
2013; Nayak et al., 2014; Reemst et al., 2016), although
these time-periods vary in a brain-region specific and sex-
specific manner (Pousset, 1994; Harry and Kraft, 2012; Schwarz
et al., 2012). Infections taking place outside this developmental
time-window will generally have a less profound impact on
microglial function as was clearly demonstrated in a study
where infection with E. coli at P30, but not at P4, failed
to induce long-term changes in glial activation and cytokine
expression (Bilbo et al., 2006). Clearly, microglial cells are
vulnerable to peripheral immune challenges in an age-related
manner that can lastingly alter the CNS immune response,
whereas mature microglial cells seem to be less vulnerable.
The next section addresses a similar shift that occurs in the
inflammatory profile of microglia as a result of the normal aging
process.
The Effect of Peripheral Infections on
Microglial Cells in the Aging Brain
Although our understanding of glial cell priming following
neonatal infections is still limited, evidence exists for similar
alterations in microglial function resulting from the aging
process (Godbout et al., 2005; Chen et al., 2008; Dilger and
Johnson, 2008; Mosher and Wyss-Coray, 2014). The previously
described microglial senescence is revealed by an overall
upregulation in inflammatory factors in the brain of aged rodents
(Lee et al., 1999; Godbout et al., 2005; Sierra et al., 2007; Frank
et al., 2010). Indeed, aged microglia show a distinct expression
profile, which differs from young mice, or in their response to
LPS (Holtman et al., 2015). Moreover, many of the genes that
are upregulated in an age-dependent manner in microglia are
associated with their activational status or profile, and with the
CNS innate immune response (Godbout et al., 2005; Cribbs et al.,
2012). This notably also occurs in neurodegenerative diseases,
like AD (Li et al., 2014).
Increased expression of the microglial activity markers
MHCII and CD11b was found in rodent models of healthy aging,
indicative of microglial priming (Godbout et al., 2005; Barrientos
et al., 2006; Henry et al., 2009; VanGuilder et al., 2011; Norden
and Godbout, 2013). An exaggerated activation of microglial
cells is indeed commonly seen in the aged brain after cytokine
(Deng et al., 2006) or peripheral LPS administration (Henry
et al., 2009) and is often accompanied by enhanced levels of pro-
inflammatory cytokines such as IL-1β, TNFα and IL-6 relative
to levels found in adult animals after the same stimuli (Ye and
Johnson, 2001; Godbout et al., 2005; Sierra et al., 2007).
The aged brain further exhibits deficits in its anti-
inflammatory mechanisms and responses, including reduced
levels of TNFβ, IL-4 and IL-10 following peripheral infection
(Ye and Johnson, 2001; Godbout et al., 2005; Sierra et al.,
2007; Wynne et al., 2010; Fenn et al., 2012). These findings are
indicative of an altered glial sensitivity/responsivity, or microglial
priming, that may result from the process of aging per se, and
is different from the microglial phenotype found in the healthy
adult brain. The underlying mechanisms that trigger these age-
dependent alterations in microglial function are unknown and
remain an important target for future research.
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Another important question is when and how the transition
occurs from a well-balanced microglial activational state in the
adult brain, into a more reactive and pro-inflammatory profile as
found in microglia in aged brains. So far, studies that compared
the inflammatory response among young, middle-aged and old
rodents, suggest that the increased inflammatory profile in
response to systemic challenges is not linear function of age, but
appears specific to the advanced age group (Deng et al., 2006;
VanGuilder et al., 2011). As no specific time-point of transition
appears to exist, it is proposed that the exact timing is individual
and based on an interaction between both intrinsic and extrinsic
factors (Luo et al., 2010), although the specific modulators of this
process remain elusive.
Thus, microglial activation during early-life makes these
cells highly sensitive to systemic infections in that period
and may shift them towards a priming-like state in a lasting
manner. A similar shift in microglial phenotype seems to occur
during aging. Although the underlying mechanisms are probably
different for both periods, the responses are fairly similar and
the parallels are striking. Importantly, in the healthy adult brain,
microglial cells seem to be relatively protected against the lasting
effects of systemic infections. The next section addresses the
impact of peripheral infections on cognition and behavior in
vulnerable brains.
ACTIVATION OF PRIMED MICROGLIA BY
SYSTEMIC INFECTIONS IMPAIRS
COGNITIVE AND BEHAVIORAL
FUNCTIONING
Microglial Cell Priming per se does not
Lead to Cognitive and Behavioral
Dysfunction
The enhanced activation of the immune system in early-life has
repeatedly been linked to a decrease in cognitive functioning later
in life, as well as in an increased risk to develop brain disorders,
such as autism and schizophrenia (Rantakallio et al., 1997;
Bilbo and Schwarz, 2009; O’Connor et al., 2014), but possibly
also neurodegenerative disease like AD and Parkinson’s disease
(Miller and O’Callaghan, 2008). In addition, an (age-related)
increase in pro-inflammatory cytokines is often accompanied by
deficits in cognition, brain plasticity, psychomotor co-ordination
and an increase in risk for neurodegenerative diseases (Jang
et al., 2010; Villeda et al., 2011; Norden and Godbout,
2013).
Together, this indicates that altered microglial function can
have a direct and profound impact on brain function. However,
exceptions exist too and several rodent studies of early-life
infection have failed to find lasting effects on cognition in
the Morris water maze (MWM), Y-maze and elevated plus
maze (Bilbo et al., 2005b; Spencer et al., 2005; Dinel et al.,
2014). Similarly, aged rats did not exhibit profound learning
problems compared with adult rats in similar tasks (Barrientos
et al., 2006; VanGuilder et al., 2011), but see (Lindner, 1997).
Moreover, the variation in cognitive performance increases
substantially among aged individuals (Drapeau et al., 2003; Bizon
et al., 2009), indicating that while aging is a risk factor for
cognitive decline, cognitive decline is no universal characteristic
of aging (Lindeboom and Weinstein, 2004; VanGuilder et al.,
2011).
Impaired Cognition and Behavior
Following Activation of Primed Microglia
by Later Peripheral Infections
Exposure to a second immunological ‘‘hit’’ can alter cognitive
function and behavior in perinatally infected as well as aged
rodents. The combination of early-life infection with LPS at
P14 and subsequent (re-)exposure to LPS during adolescence
(P30) or adulthood (P90) revealed impairments in spatial
memory performance in mice as tested by the Y-maze (Dinel
et al., 2014). In addition, rats infected with E. coli at P4
displayed impaired memory in a contextual fear conditioning
paradigm after receiving LPS in adulthood (Bilbo et al.,
2005b). Exposing P4 infected rats to LPS in adulthood further
impaired the long-term (48 h), but not the short-term (1 h)
memory for contextual fear experiences, indicating that the
deficit was in part mediated by the hippocampus (Bilbo
et al., 2006). Again, evidence suggests the existence of a
vulnerable time-window, as infection at P30 did not result in
LPS-induced memory impairments later in life (Bilbo et al.,
2006).
Peripheral immune challenges in aged rodents similarly
induce cognitive and behavioral impairments. Chen et al. (2008)
e.g., found impaired spatial learning after LPS injection in
22-month old mice compared to younger cohorts, as tested
in the radial arm water maze. Moreover, LPS in aged mice
induced hippocampal-dependent memory deficits in contextual
fear conditioning (Burton and Johnson, 2012). Consistent with
this, 24month old rats exhibited worsened hippocampal memory
consolidation in the MWM and in a contextual fear conditioning
paradigm after E. coli infection relative to 3 month old rats
(Barrientos et al., 2006, 2009).
These hippocampal-dependent cognitive impairments were
accompanied by additional behavioral alterations. Several studies
revealed that aged rodents displayed a prolonged and exaggerated
sickness response after immune stimulation with either E. coli
or LPS, which was characterized by longer anorectic behavior,
more weight loss and prolonged social withdrawal behavior
(Godbout et al., 2005; Huang et al., 2008; Wynne et al., 2010).
In addition to a delayed recovery from sickness, aged mice
showed prolonged depressive-like behavior in response to LPS
administration compared to adult mice (Godbout et al., 2008).
While also aspects of stress may be relevant here, it is
noteworthy that not only peripheral infections may serve as
a second ‘‘hit’’ for immune cells. A study of Bilbo (2010)
revealed a combined effect of early-life infection and aging,
where the process of aging itself was considered a second hit.
Rats infected with E. coli at P4 were tested for learning and
memory at either 2 months or 16 months of age. Neonatal-
infected rats exhibited memory deficits in the MWM and a fear
conditioning task when tested as aging animals (16 months),
suggesting that early-life infection may set off a less successful
Frontiers in Human Neuroscience | www.frontiersin.org 4 August 2016 | Volume 10 | Article 398
Hoeijmakers et al. Microglial Priming and Alzheimer’s Disease
aging trajectory. The following section will deal with the role of
microglia-released cytokines in these cognitive and behavioral
deficits.
Role of Cytokines in Mediating Acute
Cognitive and Behavioral Impairments
Almost all cognitive and behavioral deficits that occur following
peripheral immune challenges in a ‘‘primed’’ brain condition,
appear to be accompanied by an enlarged and prolonged pro-
inflammatory cytokine response (Bilbo et al., 2005a; Godbout
et al., 2005; Chen et al., 2008; Barrientos et al., 2009; Henry
et al., 2009; Püntener et al., 2012). For instance, the cognitive
impairments found in early-life infected rodents that were
challenged as adults with LPS, were paralleled by a large increase
of both IL-1β and TNFα within the first few hours post-LPS in
their hippocampus compared to vehicle treated rodents (Bilbo
et al., 2008; Dinel et al., 2014). Similarly, a peripheral injection
of LPS caused an exaggerated increase of IL-1β, IL-6 and TNFα
in brains of aged mice relative to adult ones (Godbout et al.,
2005; Barrientos et al., 2006; Chen et al., 2008; Henry et al., 2009),
responses that notable lasted up to 24 h. These findings suggest
an important role for these particular cytokines in the induction
of behavioral and cognitive alterations.
Expression of the cytokine IL-1β in the brain has been
implicated in mediating (lasting) central effects following
peripheral immune challenges. Both peripheral administration of
IL-1β per se (Oitzl et al., 1993; Gibertini et al., 1995) or direct
injection of IL-1β into the hippocampus (Barrientos et al., 2002)
already induce memory deficits, thus linking an enlarged IL-1β
response to the hippocampal-dependent impairments seen after
immune challenges. In agreement, IL-1 receptors are present
throughout the brain including expression in the hippocampal
formation (Farrar et al., 1987; Cunningham et al., 1991; VanDam
et al., 1996). Prevention of the IL-1β increase, e.g., by inhibiting
IL-1β synthesis (Bilbo et al., 2005a) or by administration of
an IL-1 receptor antagonist (Terrando et al., 2010), averted
the memory impairments. Furthermore, basal levels of IL-1β of
neonatally-infected and aged animals did not differ from their
controls prior to a second immune challenge. This agrees with the
lack of cognitive and behavioral differences between these groups
prior to a secondary stimulus (Bilbo et al., 2005a; Spencer et al.,
2005; Barrientos et al., 2009; Dinel et al., 2014).
Next to an exaggerated response in pro-inflammatory
cytokines to a secondary immune challenge, also the anti-
inflammatory response is altered. Whereas the rise in LPS-
inducted TNFβ expression in young animals is normally
required to attenuate the IL-1β response, TNFβ mRNA
expression remained unaffected after LPS exposure in
aged rats (Wynne et al., 2010). Similarly, microglia from
aged mice were less sensitive to anti-inflammatory effects
of IL-4 (Fenn et al., 2012). In contrast to these data, LPS
exposure upregulated anti-inflammatory IL-10 levels in aged
mice compared to adults (Henry et al., 2009), although
Wynne et al. (2010) found no upregulation of IL-10.
As IL-10 is an inhibitor of IL-1β production (de Waal
Malefyt et al., 1991; Ledeboer et al., 2002; Lynch et al.,
2004), IL-10 might be ineffective as an anti-inflammatory
mediator as both appear strongly upregulated in
aged animals.
Taken together, activation of primed glial cells by peripheral
infections can result in acute hippocampal-dependent cognitive
deficits. Whereas sickness behavior usually is an adaptive
and reversible process, this response is exaggerated and of
an extended duration in animals with primed microglia. The
described impairments are mediated by a discordant central
inflammatory response, as revealed by enhanced and prolonged
production of pro-inflammatory cytokines and a decreased
production and effectiveness of anti-inflammatory cytokines. As
laboratory animals are housed under (specific) pathogen free
conditions, it is important to consider whether these results can
be translated to the human situation. Clinical evidence points to
similar alterations in cognition in response to systemic infections
in vulnerable individuals.
Systemic Infections Contribute to
Cognitive and Behavioral Dysfunction:
Evidence from Human Studies
Although infections during early-life can have serious
consequences for the developing brain, the underlying
mechanisms are not well understood. Similar to animal studies,
human studies also suggest that a rise in pro-inflammatory
cytokine levels during critical periods can contribute to later-
life impairments in cognition (Brown, 2012; Meldrum et al.,
2013). Inflammatory factors in preterm infants are found
to be associated with cerebral lesions (Duggan et al., 2001)
and cognitive impairments in early childhood (O’Shea et al.,
2013). Increased levels of IL-1β, TNFα and IL-6 were found in
cord blood and cerebrospinal fluid of infants suffering from
perinatal complications, including those with sepsis or bacterial
meningitis (Miller et al., 1990; Mustafa et al., 1990; Santana
et al., 2001). In addition to these acute elevations in cytokine
levels, the presence of particularly the pro-inflammatory
cytokines in the neonatal blood turned out to be an important
predictor of adverse outcomes on neurological functioning
in later life (Dammann and Leviton, 2004; Adams-Chapman
and Stoll, 2006; Brown and Derkits, 2010; Hagberg et al.,
2012), suggesting an important role for early-life microglial
activation in mediating long-term adverse outcomes in
humans.
Despite these suggestive findings, definitive evidence for
a priming-like effect of perinatal infections in humans is
lacking. This is due to the fact that human studies are
accompanied by technical and ethical difficulties. Several studies
further posit the need for a ‘‘two-hit" event, building on the
hypothesis that a combination of a perinatal infection and a
subsequent challenge (e.g., later stress or infection) is required
to trigger the manifestation of a disorder, with schizophrenia
being one of the best known examples (Feigenson et al.,
2014). This suggests that early-life events may (re-)program
the brain to become susceptible to challenges later in life
(Lahiri and Maloney, 2010). Experimental data to support
these hypotheses is, however, limited and evidence for specific
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reprogramming of the neuroimmune system and microglial
cells following perinatal infection in humans is not provided to
date.
On the other hand, studies on human aging have provided
evidence for an enhanced activation of microglial cells. An
activated morphology of microglia has been reported in brains
of aged humans (Sheng et al., 1998). Similarly, translocator
protein tracers indicate elevated microglial activation in aged as
well as AD patients notably in close correlation with cognito-
mnemonic scores (Yokokura et al., 2016). Moreover, the gene
expression profile in the aged brain indicates a clear upregulation
of immune-related genes, including an enhanced expression of
IL-1β, TNFα and IL-6 (Cribbs et al., 2012). Since these changes
are associated with normal, healthy aging, the question remains
whether the immunological response to a subsequent challenge
is changed to a priming-like response under aging conditions.
A common phenomenon in elderly is delirium; an acute,
transient change in attention and cognition in response
to infection or surgery (Wofford et al., 1996; Van Gool
et al., 2010). Delirium is strongly associated with an elevated
risk of cognitive disorders (Kat et al., 2008; Girard et al.,
2010), and the appearance of delirium may further indicate
underlying or undiagnosed dementia (Rahkonen et al., 2000;
Van den Boogaard et al., 2011). Another study demonstrated
increased disturbances in cognitive processing in response
to upper respiratory tract infections in older relative to
younger individuals (Bucks et al., 2008), indicating an enhanced
susceptibility of elderly to cognitive problems after systemic
infections compared to adults. The etiology of delirium might
further be related to neuroinflammation, as biomarker analysis
has associated an elevation of several inflammatory factors
(among others, C-reactive protein, procalcitonin and IL-8) with
the duration of the delirium or brain dysfunction (McGrane
et al., 2011; Van den Boogaard et al., 2011). It has also
been suggested that delirium can be the result of microglial
overactivation or microglial priming (Van Gool et al., 2010),
while it can, according to others, also result from primary
astrocytic failure (Sfera et al., 2015). Altogether, these studies
indicate that inflammation can play an important role in the
manifestation of behavioral deficits in the vulnerable, aged
human brain.
Although there is no evidence for consequences of neonatal
infection for the later-life neuroimmunological profile in
humans, human aging seems to be associated with an increase
in the vulnerability to behavioral and cognitive impairments
following systemic immune activation. The pathophysiology
of delirium and the mechanisms underlying aging-related
vulnerability of the brain for inflammatory insults are, however,
not clear to date. Although the cognitive and behavioral
impairments following immune challenges are generally acute
and transient in nature (Murray et al., 2012; Püntener et al.,
2012), delirium in elderly also reveals prolonged consequences in
the form of cognitive disorders and dementia (Kat et al., 2008;
Girard et al., 2010). This raises the question as to whether an
inflammatory insult can also have implications for the initiation
or progression of neurodegenerative diseases with a suspected
neuroinflammatory component. In the next section, we will
therefore discuss the possible role of systemic infections in the
initiation and progression of AD.
SYSTEMIC IMMUNE CHALLENGES
CONTRIBUTE TO INITIATION AND
PROGRESSION OF AD
Currently, there is little doubt that the increased inflammatory
profile after peripheral infections in adults eventually subsides
and that microglia return to their pre-activated phenotype.
Generally, this is accompanied by the resolution of the acute
cognitive and behavioral changes (Cunningham, 2013). If this
response is not properly controlled, a lasting overexpression
of specific microglia-mediated cytokine profiles may ensue,
which may aggravate (aspects of) AD neuropathology (Mrak
and Griffin, 2005; Mhatre et al., 2015). Inflammation related
factors actually seem to precede the neuropathological changes
in AD (Hoozemans et al., 2006), suggesting their involvement
already in the early pathological stages. Also other inflammation-
related issues have been re-gaining interest recently and are of
considerable relevance for AD etiology (Itzhaki et al., 2016). In
the next sections, the possible contribution of the microglial
response to infection for the initiation and progression of AD
pathology will be discussed.
Systemic Immune Challenges Contribute
to Initiation and Progression of AD-Like
Neuropathology
AD neuropathology is generally modeled using transgenic
models of human genes linked to the development of the familial
form of AD, including genes that encode for proteins that
accumulate in neurofibrillary tangles and Aβ plaques. Several
studies have attempted to examine the effects of peripheral
administration of infectious agents on the progression of AD-like
pathology in both transgenic animals and wild-type animals.
For instance, a single viral administration of mouse hepatitis
virus in the triple transgenic mouse model of AD (3x TgAD)
resulted in a marked exacerbation of tau pathological features
compared to saline injected mice (Sy et al., 2011). Also, a single
LPS challenge already altered amyloid precursor protein (APP)
expression, parallel to elevated IL-1β and IL-6 levels (Brugg et al.,
1995).
Studies on early-life infection have found remarkable
evidence for changes in AD-related neuropathological changes
already after a single early-life infection. Wild-type mice
exposed to viral polyinosinic:polycytidylic acid during late
gestation were predisposed to develop AD-like pathology during
the course of aging. Moreover, a second systemic immune
challenge in adulthood exacerbated this phenotype and drove
Alzheimer-like neuropathology, as was revealed by increased
APP deposition, altered tau phosphorylation, enhanced glia
activation and a chronic elevation of pro-inflammatory cytokines
(Krstic et al., 2012). These findings stress the crucial role that
inflammation and possibly microglial cell priming effects, e.g.,
due to maternal or neonatal immune activation, may play in
mediating these and other later developing neurodegenerative
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effects (Krstic and Knuesel, 2013; Knuesel et al., 2014). Similarly,
systemic infection with polyinosinic:polycytidylic acid in an
animal model of prion disease led to an accelerated progression
of the neurodegenerative phenotype (Field et al., 2010),
consistent with observations showing that single systemic
challenges is a shared environmental risk factor across several
brain disorders (Knuesel et al., 2014) and indicating they may be
an important factor in the initiation or progression of AD-like
pathology.
In addition to these studies of single inflammatory
episodes, others using repeated administration of infectious
agents also reported effects on the progression of
AD-related neuropathology. For instance, repeated peripheral
administration of LPS (twice weekly for 6 weeks) to middle-aged
3x TgADmice led to an increased severity of tau phosphorylation
(Sy et al., 2011), in accordance with a similar study performed
in younger 3x TgAD mice (Kitazawa et al., 2005). Interestingly,
these results were at least partly mediated by a sustained
overexpression of the cytokine IL-1β (Ghosh et al., 2013), and
the Aβ burden in these same animals was reduced after IL-1β
overexpression. Repeated LPS administration for several weeks
further affected amyloid processing directly by augmenting
amyloidogenic protein expression and APP processing, leading
to an increase in Aβ generation compared to saline injected
mice (Sheng et al., 2003; Lee et al., 2008). This heightened
accumulation of Aβ containing plaque deposition resulted
from increased activity of β and γ secretases in response to
LPS-induced neuroinflammation (Lee et al., 2008). Lastly, in the
3x TgAD model, twice-weekly LPS administration for 4 weeks
increased APP protein accumulation (McAlpine et al., 2009).
These findings were overall associated with microglial-induced
overexpression of pro-inflammatory cytokines, among which
IL-1β and TNFα (McAlpine et al., 2009; Kyrkanides et al., 2011),
and could also be blocked by use of anti-inflammatory drugs
(Lee et al., 2008; McAlpine et al., 2009). The aggravation of AD
related neuropathology following infection can be the direct
result of changed microglial cell function, but can also be a
consequence of indirect effects of the inflammatory factors on
downstream cellular cascades linked to AD processing (for a
review see Cunningham, 2013).
Most aforementioned studies make use of repeated LPS
administration to mimic peripheral inflammation and an
important point is what this stimulus then mimicks. The
dosing regimen used in these studies is rather prolonged,
making it crucial to investigate whether this mimics a chronic
form of systemic inflammation or rather multiple separate
infections. Even a milder immunological challenge appears to
support the hypothesis that systemic infections contribute to
both progression of AD-like tauopathy and Aβ accumulation.
Moreover, this relationship seems to be mediated, at least partly,
by a microglia-induced exaggerated cytokine response. In this
respect, attention has recently been re-drawn to older studies
in which specific microbes have been causally implicated in AD
etiology (Itzhaki et al., 2016). These included herpes simplex
virus, chlamydia etc., that can remain latent in the body for years,
can trigger immune responses and are found in human brain
as well.
Given the impact that systemic insults may have on AD-like
neuropathology, an important point is whether transgenic
animal models mimicking a genetic, familial variant of AD, are
a good representation of the development of sporadic AD in
humans (Kitazawa et al., 2012). Regardless of whether AD is
induced sporadically or genetically, all AD cases seem to develop
similar neuropathological characteristics, suggesting that animal
models are still an important tool to investigate the mechanisms
underlying these features (Kitazawa et al., 2012). Peripheral
infection in transgenic models, and also in wild-type animals
revealed similar effects on AD-related genes and processes,
indicating an association between peripheral infections and
progression of AD-like pathology.
Systemic Immune Challenges Exacerbate
Cognitive Decline in AD Patients
It has been proposed that the stage, or threshold, for AD onset
and severity can possibly be set early in life, since early-life
infections may increase the risk of developing AD in later life
(Bilbo and Schwarz, 2009; Lahiri and Maloney, 2010). However,
clinical and pre-clinical support is limited (Borenstein et al.,
2006) and a causal relation is hence difficult to study as it
is complicated by the long time period between infection and
disease onset.
Several studies on infections throughout life and AD
suggest a relationship between systemic inflammation and
different hallmarks of AD. A single episode of pneumonia, a
common cause of illness worldwide, resulted in an accelerated
development of dementia in elderly (Shah et al., 2013). Indeed,
the incidence of two or more infections of unspecified type over
a period of 4 years was also associated with an increased risk
of AD (Dunn et al., 2005). Plasma inflammatory proteins were
further found to be increased already 5 years prior to the clinical
onset of dementia when compared to age-matched controls (Lim
et al., 2015), though this can also be attributed to confounding
chronic inflammatory diseases as diabetes or atherosclerosis in
these patients.
Still, a comparison of the infectious burden, consisting of
herpes simplex virus type 1 (HSV-1), Borrelia burgdorferi,
Chlamydophila pneumonia, Helicobacter pylori and
cytomegalovirus, between healthy elderly and AD patients
revealed a heightened infectious burden in AD patients (Bu et al.,
2015) that was associated with worse cognitive function and
higher levels of inflammatory cytokines, and higher levels of Aβ.
An association between AD neuropathology and HSV-1 was also
demonstrated in a study on home-dwelling elderly where HSV-1
was more common among those with lower MMSE scores
(Strandberg et al., 2004). Moreover, reactivation of HSV-1, as
indicated by heightened levels of anti-HSV antibodies, leads to
increased accumulation of Aβ in the brain (Féart et al., 2011;
Itzhaki et al., 2016).
Similarly, periodontitis is known to augment levels of
circulating TNFα in AD patients (Kamer et al., 2009), although
IL-1β and IL-6 were not elevated. Additional inflammatory
events in AD patients were associated with elevated baseline
levels of TNFα (Holmes et al., 2009) and IL-1β (Holmes et al.,
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2003) and with an increased rate of cognitive decline over
a 2 or 6-month period. On the other hand, individuals with
low baseline levels of these cytokines demonstrated more stable
cognitive function over time (Holmes et al., 2009). Although
such effects were not always found (Holmes and Cotterell, 2009),
they support the idea that a heightened inflammatory state
exacerbated AD-related cognitive decline.
The above-mentioned studies all suggest a possible role for
systemic infections, and subsequently a deregulated microglial
response, as an etiological factor relevant for cognitive decline
in general, and for AD progression in particular. Treatment of
infections and vaccination against common infectious agents
may thus, to some extent, protect against the later development
or progression of AD (Verreault et al., 2001). However, since
AD pathology is known to start many years before the clinical
onset of symptoms (Morris, 2005), it is important to consider
whether systemic infections contribute to the initiation of AD, or
whether they accelerate ongoing processes, which would result
in an earlier appearance of clinical signs and symptoms. In the
next section, the discordant inflammatory response as a potential
target for intervention will be addressed.
OPPORTUNITIES TO COUNTERACT THE
DETRIMENTAL EFFECTS OF SYSTEMIC
INFECTIONS
Given the detrimental effects of systemic infections on brain
function and aspects of AD, it is important to think of
strategies to counteract these consequences. Considering the
above, the microglia-mediated immune response forms an
important target. One of the possibilities to interfere with
neuroinflammation is by attenuating the aberrant microglial
and pro-inflammatory response (Cunningham, 2013; Lim
et al., 2015). Indeed, blocking IL-1β significantly reduced
neuroinflammation, slowed down cognitive decline and
attenuated tau pathology in transgenic mouse models of
AD (Kitazawa et al., 2011). Inhibiting TNFα had similar
beneficial effects in various animal models (Belarbi et al., 2012;
Cunningham, 2013; Camara et al., 2015).
Also, inhibiting other inflammatory cascades, including
caspases and prostaglandins was e.g., followed by a decreased
neurotoxicity and a reduction of AD-like pathology (Medeiros
et al., 2013; Dunn et al., 2015; Heneka et al., 2015). Long-term
use of NSAIDs in human, a known inhibitor of prostaglandins,
is indicated as a protective factor for AD (Vlad et al., 2008).
However, the administration of NSAIDs during the stage of
established disease failed to further slow down progression,
demonstrating a crucial role for timing of the intervention, given
that AD pathology starts several years before clinical symptoms
emerge (Morris, 2005; Rubio-Perez and Morillas-Ruiz, 2012).
In contrast to these findings, boosting the pro-inflammatory
response could prevent the initiation or progression of
established AD neuropathology (Guillot-Sestier et al., 2015b).
For instance, chronic over-expression of IL-1β (Shaftel et al.,
2007; Matousek et al., 2012), or a reduced amount of anti-
inflammatory IL-10 can reduce Aβ plaques in animal models
of AD (Guillot-Sestier et al., 2015a). This effect was mediated
by an increased ability of microglial cells to phagocyte Aβ
plaques and supported by the finding that overexpression
of anti-inflammatory IL-10 increased Aβ plaque formation
(Chakrabarty et al., 2015).
It is important to understand how an enhanced inflammatory
response can exert both adverse and protective effects. The
time window of intervention could be one possible explanation,
taking into account the pathological stage, age of the animal
and basal level of inflammation. Beneficial effects of a boosted
inflammatory system is further often investigated using chronic
models, i.e., transgenic lines, viral expression regulation, and
in relatively young (up to 12 months old) adult animals
(Shaftel et al., 2007; Matousek et al., 2012; Guillot-Sestier et al.,
2015a). Whether these beneficial effects appear also under acute
pathological conditions or in aged individuals with established
microglial dysfunction remains to be investigated.
The existence of both beneficial and detrimental
consequences of microglia-mediated inflammation for the
development AD pathology indicates the complexity of the
inflammatory system. Even though enhanced inflammation can
have protective effects in animals, systemic infections in both
animals and humans generally seem to do more harm than
good. The possible transition from healthy microglial activation
towards detrimental microglial activation requires a better
understanding of the complex machinery by which microglia
switch their phenotype. Interestingly, while this may to some
extent depend on different microglia subtypes that may differ
between different brain regions (Doorn et al., 2015), mechanisms
underlying a switch in microglia phenotype and function are
currently under investigation, and epigenetic changes have
recently been implicated in the changes in microglia-mediated
immune responses (Netea et al., 2011, 2016; Garden, 2013).
A study of Cao et al. (2015) revealed that microglia
exposed to early-life inflammation carry an ‘‘innate immune
memory’’ that is regulated by epigenetic processes including
histone acetylation and miRNA signaling. These modifications
are thought to allow further activation of microglial cells
by subsequent immune challenges, thus the primed response
to immune insults (Püntener et al., 2012; Cao et al., 2015).
Additionally, both LPS-treated microglia (Cho et al., 2015) and
microglia of aged animals (Matt and Johnson, 2015) display
hypomethylation of the IL-1β gene promoter, which may explain
the heightened microglial activation and pro-inflammatory
cytokine levels in response to an immune challenge. Besides, it
has been suggested that early-life insults may result in epigenetic
regulation of promoter regions of genes involved in AD, thereby
possibly explaining enlarged vulnerability of AD after subsequent
immune challenges (Lahiri and Maloney, 2010; Krstic et al.,
2012).
Mechanisms of Action
The epigenetic machinery is of particular interest as it may be
able to at least partly reprogram the innate immune system,
and allow to reverse or to prevent the primed microglial
responses. Even though specific reprogramming of the primed
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FIGURE 1 | Schematic representation of the consequences of microglial priming by neonatal infection or aging. Microglia are generally present as
surveying, quiescent cells in the brain. Infection during the neonatal period and aging lead to priming of the microglia. Upon a subsequent inflammatory episode,
such as systemic infection or other immunological challenges, the microglial response of the primed cells is exaggerated, leading to increased pro-inflammatory
cytokine release. Ultimately the imbalanced inflammatory response ultimatley impacts CNS function that can lead to cognitive dysfunction and neuropathological
changes associated with Alzheimer’s disease (AD) in the brain.
cells is currently beyond our capabilities, various factors are
known to induce epigenetic changes that can programmicroglial
cell functioning. Microglial cell activation can for instance be
suppressed by epigenetic modulation with histone deacetylase
inhibitors, preventing an inflammatory state (Kannan et al.,
2013). In addition, neonatal handling early in life is an
intervention that consists of brief, and often repeated, daily
separations of the dam and her pups during the early life period,
generally from P3-P10. This is known to enhance the extent of
maternal care upon the reunion of the dam with her pups, which
is associated with beneficial effects in later life (Meaney et al.,
1988; Plotsky and Meaney, 1993; Lesuis et al., 2016). Neonatal
handling also increased the expression of the anti-inflammatory
cytokine IL-10 in the nucleus accumbens by microglia-specific
epigenetic programming (Schwarz et al., 2011). Additionally,
neonatal handling of rat pups that had been infected with E. coli
at P4, prevented both the exaggerated IL-1β response and the
memory impairments following exposure to LPS later in life
(Bilbo et al., 2007), illustrating the possibility to reverse (aspects
of) microglial priming. Although it was not investigated whether
this effect was truly established via epigenetic regulation, this
might be a likely possibility.
One well-known factor to regulate epigenetic machinery is
nutrition (Sezgin and Dincer, 2014). Nutritional intervention
may thus be a convenient method for reversing inappropriate
expression or silencing of certain genes (Weaver et al., 2005;
Lahiri and Maloney, 2010). Methyl group donors (among others
the essential dietary components methionine, choline, betaine,
vitamin B6 and B12) that are present in the maternal diet
during fetal brain development are crucial for modulating
offspring microglial function, including programming of the
neuroimmune response (Hollingsworth et al., 2008; Canani
et al., 2011; Bolton and Bilbo, 2014). Additionally, different
nutritional components are currently tested as intervention for
different aging-related adversities, including the inflammatory
state and cognitive decline (Meydani, 2001; Luchsinger and
Mayeux, 2004; Cole et al., 2005; Uribarri et al., 2007; Külzow et al.,
2016). Nutritional factors could further reverse the epigenetic
alterations that may have resulted from early-life experiences
in adulthood (Weaver et al., 2005). However, it is currently
unknown whether dietary interventions starting at advanced
ages, will exert a similar effect. Particular diets including high
levels of omega-3 fatty acids, fruits and vegetables may enhance
cognitive functioning and memory accompanied by a reduced
risk of developing AD in elderly (Joseph et al., 2009; Jang et al.,
2010; Lopez et al., 2011). Besides, an anti-oxidant rich diet slowed
down AD progression (Subash et al., 2014). Since many nutrients
in these specific diets can be linked to epigenetic processes, it is
likely that these nutrients positively affect and/or can possibly
normalize an initially ‘‘inappropriate’’ epigenetic status of the
older brain (for a review, see Sezgin and Dincer, 2014). However,
nutrients may also exert their effects independent of epigenetic
modulation, e.g., via (in)direct regulation of microglial activation
or cytokine production, or on the general metabolism or stress
regulation.
Altogether, these studies indicate that both pharmacological
and non-pharmacological interventions may potentially
modulate inappropriate microglial cell function by decreasing
the (chronic) inflammatory state. Although these results seem
promising, it should be kept in mind that microglial function
is a complex machinery of interacting mechanisms, whereby
intervening in one mechanism may have consequences for
the other.
CONCLUSION
In this review, we highlighted parallels between the microglial
responses to immune insults in the aging brain, and in studies
of early-life infection. In both cases, the normal homeostatic
role of microglial cells becomes aberrant and dysregulated,
leading to an increased susceptibility of these cells to subsequent
immune challenges, an effect known as priming. Interestingly,
microglial cells from young adult and middle-aged brains seem
to be relatively protected in this respect. Systemic inflammatory
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episodes, activating the primed glia cells, induce an imbalanced
secretion of pro-inflammatory and anti-inflammatory cytokines
and have a negative impact on CNS function, as revealed
by cognitive deficits and prolonged behavioral alterations
(Figure 1).
Moreover, although these impairments are of a transient
nature, the exaggerated cytokine expression can also contribute
to the induction of neuropathological changes resembling human
AD pathology in rodents. Infection-related, exacerbation of pro-
inflammatory cytokines is also associated with worsening of
clinical symptoms and pathology in AD patients. We therefore
may conclude that systemic infections in individuals with
primed microglia may be an additional risk factor for AD
acceleration. The profound role of microglial cells in mediating
the inflammatory profile in the CNS makes them an important
target for therapeutic strategies.
A better understanding is needed of how microglial cells
respond to their environment and e.g., switch phenotype
following (early-life) insults, or during the aging process, and
how they interact with the peripheral immune system in response
to systemic infections. This is required if we are to target the
inflammatory profile in general and microglia in particular. Of
course, there are manymore risk factors than systemic infections.
However, given the aging population, the increasing knowledge
about the detrimental effects of neonatal infections, and an
environment in which systemic infections are very common, the
contribution of systemic immune challenges to the progression
of AD can no longer be ignored, and form an attractive target for
future research and therapeutic intervention.
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